Extended follow-up of a Phase II trial in relapsed, refractory multiple myeloma: Final time-to-event results from the SUMMIT trial

Cancer

Volumn 106, Issue 6, 2006, Pages 1316-1319

  Richardson, Paul G ^a,k   Barlogie, Bart ^b   Berenson, James ^c   Singhal, Seema ^d   Jagannath, Sundar ^e   Irwin, David H ^f   Rajkumar, S Vincent ^g   Srkalovic, Gordan ^h,j   Alsina, Melissa ⁱ   Anderson, Kenneth C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^f Alta Bates Cancer Center   (United States)

^g MAYO CLINIC   (United States)

^h TAUSSIG CANCER INSTITUTE   (United States)

ⁱ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^j Sparrow Cancer Center   (United States)

^k DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

Bortezomib; Dexamethasone; Multiple myeloma; Proteasome inhibitor

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; PROTEASOME INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DIAGNOSTIC VALUE; DOSE TIME EFFECT RELATION; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; RELAPSE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DEXAMETHASONE; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PYRAZINES; SALVAGE THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 33644844108     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21740     Document Type: Article

References (15)

1. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071-3076.
2. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002;62:4996-5000.
3. Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003;9:1136-1144.
4. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101:2377-2380.
5. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165-172.
6. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20:4420-4427.
7. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.
8. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib demonstrates superior efficacy to high-dose dexamethasone in relapsed multiple myeloma: final report of the APEX study. Paper presented at: American Society of Hematology 46th Annual Meeting, December 4-7, 2004; San Diego, CA. Available at: http://wwwabstracts2viewcom/hem_sandiego2004/. Abstract 336.5.
9. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115-1123.
10. Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004;79:867-874.
11. Berenson JR, Jagannath S, Barlogie B, et al. The safety of prolonged therapy with the proteasome inhibitor bortezomib (Velcade) in relapsed and/or refractory multiple myeloma (MM) [abstract]. Hematol J. 2004;5(suppl 2):S129.
12. Cavenagh JD, Curry N, Stec J, et al. PAD therapy (bortezomib, doxorubicin and dexamethasone) for untreated multiple myeloma (MM) [abstract]. J Clin Oncol. 2004;22(14S):S570. Abstract 6550.
13. Jagannath S, Durie BGM, Camacho E, et al. First-line therapy with bortezomib (formerly PS-341) in patients with multiple myeloma (MM) [abstract]. J Clin Oncol. 2004;22(14S):S570. Abstract 6551.
14. Goy A, Younes A, McLaughlin P, et al. Update on a phase (ph) 2 study of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin's lymphomas (NHL) [abstract]. J Clin Oncol. 2004;22(14S):S577. Abstract 6581.
15. O'Connor OA. Marked clinical activity of the novel proteasome inhibitor bortezomib in patients with relapsed follicular (RL) and mantle cell lymphoma (MCL) [abstract]. J Clin Oncol. 2004;22(14S):S578. Abstract 6582.